HC Wainwright Issues Optimistic Estimate for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Analysts at HC Wainwright raised their Q1 2026 earnings estimates for MiNK Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.77) per share for the quarter, up from their prior forecast of ($0.78). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($3.50) EPS, FY2027 earnings at ($3.58) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.12) EPS.

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $10.69 on Friday. The business’s 50-day moving average is $10.88 and its two-hundred day moving average is $12.22. The company has a market capitalization of $53.13 million, a P/E ratio of -3.60 and a beta of 0.35. MiNK Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. 2.87% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting MiNK Therapeutics

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $35 price target (roughly 227% above the recent open), reinforcing broker support for INKT and providing a clear upside anchor for investors. Buy Rating Article
• Positive Sentiment: HC Wainwright raised several near‑term and FY estimates (Q1–Q3 2026, FY2026–FY2028), indicating the analyst now models smaller losses over the next few years — a constructive trend for valuation and investor sentiment even though the company remains loss-making.
• Positive Sentiment: MiNK’s agenT‑797 abstract was accepted for presentation at the ASGCT Annual Meeting (May) and an abstract accepted at the ATS conference (May), increasing scientific visibility and potential partnership/collaboration interest ahead of conference data releases. ASGCT Presentation Article ATS Presentation Article
• Neutral Sentiment: HC Wainwright published a long‑range view that includes a FY2030 EPS projection of $1.31 — a material turn to profitability in their model but distant and subject to development/execution risk.
• Negative Sentiment: HC Wainwright trimmed the Q4 2026 EPS forecast slightly (from ($0.92) to ($0.95)) and materially cut FY2029 from $0.49 to ($0.12), introducing uncertainty about the timing and durability of the path to positive earnings.
• Negative Sentiment: Insider selling and mixed hedge‑fund activity were noted in recent coverage (several insider sales reported), which can weigh on sentiment for a small‑cap biotech where insider moves are closely watched by the market. Quiver Article

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.